Exhibit F

This Act is current to June 17, 2020

See the Tables of Legislative Changes for this Act's legislative history, including any changes not in force.

OPIOID DAMAGES AND HEALTH CARE COSTS RECOVERY ACT

[SBC 2018] CHAPTER 35

Assented to October 31, 2018

Contents

Definitions and interpretation

1 (1) In this Act:

"cost of health care benefits" means the sum of

(a) the present value of the total expenditure by the government for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and

(b) the present value of the estimated total expenditure by the government for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness;

"disease, injuryo rilln ess"i ncludesp roblematics ubstance use, addictionan d generald eteriorationo f health;

"healthca re benefits"m eans

(a) benefitsas d efinedu ndert he *HospitalI nsurance Act*,

(b) benefitsas d efinedu ndert he *Laboratory ServicesA ct*,

(c) benefitsas d efinedu ndert he *Medicare ProtectionA ct*,

(d) benefitsas d efinedu ndert he *PharmaceuticalSer vicesA ct*,

(e) paymentsm ade byt he governmentu ndert he *ContinuingCar e Act*, and

(f) otherex pendituresb yt he government, made directlyo rt hrougho ne orm ore agentso ro theri ntermediate bodies, forp rograms, services, benefitso rs imilarm attersas sociatedw ithd isease, injuryo ri llness;

"insuredp erson"m eans

(a) a person, including a deceasedp erson, forw homh ealthc are benefits have beenp rovided, or

(b) a personfo rw homh ealthc are benefitsc ouldr easonablyb e expected tob e provided;

"jointv enture"m eansan as sociationo f 2o rm ore persons, if

(a) the relationshipam ongt he personsd oesn otc onstitute a corporation, partnershipo rt rust, and

(b) the personseac hh ave anu ndividedi nteresti nas setso f the association;

"manufacture"i ncludes, foran o pioidp roduct, thep roduction, assemblyan d packagingo f the opioidp roduct;

"manufacturer"m eans a personw hom anufactureso rh asm anufacturedan opioidp roductan d a personw ho, int he pasto rc urrently,

(a) causes, directlyo ri ndirectly, throughar rangementsw ithc ontractors, subcontractors, licensees, franchiseeso ro thers, the manufacture of ano pioidp roduct,

(b) foran yfi scaly earo f the person, derivesat l east1 0%o f revenues, determinedo n a consolidatedb asisi nac cordance withg enerally acceptedac countingp rinciplesi nCan ada, fromt he manufacture or promotiono f opioidp roductsb yt hatp ersono rb yo therp ersons,

(c) engagesi no rc auses, directlyo ri ndirectly, otherp ersonst oen gage in promotingan o pioidp roduct, or

(d) is a trade associationp rimarilyen gagedi n

(i) advancingt he interestso f manufacturers,

(ii) promotingan o pioidp roduct, or

(iii) causing, directlyo ri ndirectly, otherp ersonst oen gage in promotingan o pioidp roduct;

"opioidp roduct"m eansan yp roductt hatc ontains

(a) a drugs eto uti nt he Schedule, or

(b) a drugp rescribedb yr egulation;

"opioid-relatedd isease, injuryo rilln ess"m eansd isease, injuryo ri llness causedo rc ontributedt ob yan i ndividual'su se orex posure toan o pioid product, whethert he opioidp roducti s

(a) int he formi nw hichi tw asm anufactured,

(b) combinedw ithan otherd rugo rs ubstance, or

(c) used, ori nt he case of exposure isp resent, in a formo rm annero ther than

(i) asp rescribedo rad visedb y a practitioner, or

(ii) asr ecommendedb yt he manufacturero f thato pioidp roduct;

"opioid-relatedw rong"m eans

(a) a tortt hati sc ommittedi nB ritishCo lumbia by a manufacturero r wholesaleran dt hatc auseso rc ontributest oo pioid-relatedd isease, injuryo ri llness, or

(b) inan ac tionu nders ection2 (1), a breach, by a manufacturero r wholesaler, of a commonl aw, equitable ors tatutoryd utyo ro bligation owedt op ersonsi nB ritishCo lumbia whoh ave usedo rb eenex posed too rm ightu se orb e exposedt oan o pioidp roduct;

"person"i ncludes a trust, jointv enture ort rade association;

"practitioner"m eans a personw ho

(a) isau thorizedu ndert he *HealthPr ofessionsA ct*o rt he *Veterinarians Act*t op rescribe orad vise ont he therapeuticv alue, contentsan d hazardso f a drugw ithint he meaningo f the *Pharmacy Operationsan d DrugSc hedulingA ct*, and

(b) isn otp rohibitedfr omp rescribinga drugt hati san o pioidp roduct;

"promote"o r **"promotion"**i ncludes, foran o pioidp roduct,

(a) the marketingo f the opioidp roduct, whetherd irecto ri ndirect,

(b) the distributiono rs ale of the opioidp roduct, and

(c) anyr esearchw ithr espectt ot he opioidp roduct;

"type of opioidp roduct"m eansan o pioidp roducti nt he formo f a pill, a capsule, ano rall iquid, a powder, ani njectable, a topicalo r a combinationo f anyo f these;

"use orexp osure", inr elationt oan o pioidp roduct, meansi ngestion, inhalation, injection, applicationo ras similationo f the opioidp roduct, whetheri ntentional oro therwise;

"wholesaler"m eans a personw hod istributes, sellso ro ffersfo rs ale opioid products

(a) top harmacies, distributorso ro therp ersonsfo rr esale, or

(b) toh ospitals, facilitieso rc are centresfo rp atientu se.

(2) The definitiono f "manufacturer" in subsection(1) doesn oti nclude

(a) ani ndividual,

(b) a wholesalero rr etailero f opioidp roductsw hoi sn otr elatedt o

(i) a personw hom anufacturesan o pioidp roduct, or

(ii) a persond escribedi np aragraph(a) o f the definitiono f "manufacturer", or

(c) a personw ho

(i) is a manufacturero nlyb ecause paragraph(b) or(c) of the definitiono f "manufacturer" appliest ot he person, and

(ii) isn otr elatedt o

(A) a personw hom anufacturesan o pioidp roduct, or

(B) a persond escribedi np aragraphs (a) or(d) of the definitiono f "manufacturer".

(3) Fort he purposeso f subsection(2) of thiss ection, a personi sr elatedt o anotherp ersoni f, directlyo ri ndirectly, the personi s

(a) anaffi liate, asd efinedi ns ection1 o f the *BusinessCo rporationsA ct*, of the otherp erson, or

(b) anaffi liate of the otherp ersono ran affi liate of anaffi liate of the otherp erson.

(4) Fort he purposeso f subsection(3) (b), a personi sd eemedt ob e anaf filiate of anotherp ersoni f the person

(a) is a corporationan dt he otherp erson, or a groupo f personsn ot dealingw itheac ho therat ar m'sl engtho f whicht he otherp ersoni sa member, owns a beneficiali nterest ins hareso f the corporation

(i) carryingat l east5 0%o f the votesf ort he electiono f directorso f the corporation, andt he votesc arriedb yt he sharesar e sufficient, if exercised, toel ect a directoro f the corporation, or

(ii) having a fairm arketv alue, including a premiumfo rc ontroli f applicable, of atl east5 0%o f the fairm arketv alue of allt he issuedan do utstandings hareso f the corporation, or

(b) is a partnership, trusto rjo intv enture, andt he otherp erson, ora groupo f personsn otd ealingw ithe acho therat ar m'sl engtho f which the otherp ersoni s a member, hasa no wnershipi nteresti nt he assets

of thatp ersont haten titiest he otherp ersono rg roupo f personst o receive atl east5 0%o f the profitso rat l east5 0%o f the assetso n the dissolution, windingu po rt erminationo f the partnership, trusto r jointv enture.

(5) Fort he purposeso f subsection(3) (b), a personi sd eemedt ob e anaf filiate of anotherp ersoni f the otherp erson, or a groupo f personsn otd ealingw itheac h otherat ar m'sl engtho f whicht he otherp ersoni s a member, hasan yd irecto r indirecti nfluence that, if exercised, wouldr esulti nc ontroli nfac to f that person, excepti f the otherp ersono rg roupo f personsd ealsat ar m'sl ength witht hatp ersonan dd erivesi nfluence solelyas a lender.

(6) Fort he purposeso f determiningt he markets hare of a defendantfo r a type of opioidp roducts oldi nB ritishCo lumbia, the courtm ustc alculate the defendant'sm arkets hare fort he type of opioidp roductb yt he following formula:

$$dms = \frac{dm}{MM} \times 100\%$$

where

dms = the defendant's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that defendant to the date of trial;

dm = the quantity of the type of opioid product manufactured or promoted by the defendant that is distributed or sold within British Columbia from the date of the earliest opioid-related wrong committed by that defendant to the date of trial;

MM = the quantity of the type of opioid product manufactured or promoted by all manufacturers or wholesalers that is purchased or dispensed within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the defendant to the date of trial.

Directa ctionb yg overnment

2 (1) The governmenth as a directan dd istinctac tionag ainst a manufacturero r wholesalert or ecovert he costo f healthc are benefitsc ausedo rc ontributedt o byan o pioid-relatedw rong.

(2) Anac tionu nders ubsection(1) isb roughtb yt he governmenti ni tso wnr ight andn oto nt he basiso f a subrogatedc laim.

(3) Inan ac tionu nders ubsection(1), the governmentm ayr ecovert he costo f healthc are benefitsw hethero rn ott here hasb eenan yr ecoveryb yo ther personsw hoh ave sufferedd amagec ausedo rc ontributedt ob yt he opioid-relatedw rongc ommittedb yt he defendant.

(4) Inan ac tionu nders ubsection(1), the governmentm ayr ecovert he costo f healthc are benefits

(a) forp articulari ndividuali nsuredp ersons, or

(b) onan ag gregate basis, for a populationo f insuredp ersons

whoh ave sufferedd amage causedo rc ontributedt ob yt he use of orex posure to a type of opioidp roduct.

(5) If the governments eeksi nan ac tionu nders ubsection(1) tor ecovert he cost of healthc are benefitso nan ag gregate basis,

(a) iti sn otn ecessary

(i) toi dentifyp articulari ndividuali nsuredp ersons,

(ii) top rove the cause of opioid-relatedd isease, injuryo ri llnessi n anyp articulari ndividuali nsuredp erson, or

(iii) top rove the costo f healthc are benefitsfo ran yp articular individuali nsuredp erson,

(b) the healthc are recordsan dd ocumentso f particulari ndividuali nsured personso rt he documentsr elatingt ot he provisiono f healthc are benefitsfo rp articulari ndividuali nsuredp ersonsar e notc ompellable exceptas p rovidedu nder a rule of law, practice orp rocedure that requirest he productiono f documentsr eliedo nb yan ex pertw itness,

(c) a personi sn otc ompellable toan swerq uestionsw ithr espectt ot he healtho f, ort he provisiono f healthc are benefitsfo r, particular individuali nsuredp ersons,

(d) despite paragraphs(b) and(c) of thiss ubsection, onap plicationb ya defendant, the courtm ayo rderd iscoveryo f a statisticallym eaningful sample of the documentsr eferredt oi np aragraph(b) of this subsection, andt he orderm usti nclude directionsc oncerningt he nature, levelo f detailan dt ype of informationt ob e disclosed, and

(e) if ano rderi sm ade underp aragraph(d) of thiss ubsection, the identityo f particulari ndividuali nsuredp ersonsm ustn otb e disclosed, andal li dentifierst hatd isclose orm ayb e usedt ot race the nameso r identitieso f anyp articulari ndividuali nsuredp ersonsm ustb e deleted froman yd ocumentsb efore the documentsar e disclosed.

Recoveryo f costo f healthca re benefits ona ggregate basis

3 (1) Inan ac tionu nders ection2 (1) fort he recoveryo f the costo f healthc are benefitso nan ag gregate basis, subsection(2) of thiss ectionap pliesi f the governmentp roves, on a balance of probabilities, that, inr especto f a type of opioidp roduct,

(a) the defendantb reached a common law, equitable ors tatutoryd utyo r obligationo wedt oi nsuredp ersons whoh ave usedo rb eenex posedt o orm ightu se orb e exposedt ot he type of opioidp roduct,

(b) usingt he type of opioidp roductc anc ause orc ontribute tod isease, injuryo ri llness, and

(c) duringal lo rp arto f the periodo f the breachr eferredt oi np aragraph (a) of thiss ubsection, the type of opioidp roduct, manufacturedo r

promotedb yt he defendant, waso fferedfo rd istributiono rs ale in BritishCo lumbia.

(2) Subjectt os ubsections(1) and(4), the courtm ustp resume that

(a) the populationo f insuredp ersonsw hou sedo rw ere exposedt ot he type of opioidp roductm anufacturedo rp romotedb yt he defendant wouldn oth ave usedo rb eenex posedt ot he productb utfo rt he breachr eferredt oi ns ubsection(1) (a), and

(b) the use orex posure describedi np aragraph (a) of thiss ubsection causedo rc ontributedt od isease, injuryo ri llnesso rt he risko f disease, injuryo ri llnessi n a portiono f the populationd escribedi n paragraph (a) of thiss ubsection.

(3) If the presumptionsu nders ubsection(2) (a) and(b) apply,

(a) the courtm ustd etermine onan ag gregate basist he costo f health care benefitsp rovidedaft ert he date of the breachr eferredt oi n subsection(1) (a) resultingfr omu se orex posure tot he type of opioid product, and

(b) eachd efendantt ow hicht he presumptionsap plyi sl iable fort he proportiono f the aggregate costr eferredt oi np aragraph (a) of this subsectioneq ualt oi tsm arkets hare int he type of opioidp roduct.

(4) The amounto f a defendant'sl iabilityas sessedu nders ubsection(3) (b) mayb e reduced, ort he proportionso f liabilityas sessedu nders ubsection(3) (b) readjustedam ongt he defendants, tot he extentt hat a defendantp roves, ona balance of probabilities, thatt he breachr eferredt oi ns ubsection(1) (a) did notc ause orc ontribute tot he use orex posure referredt oi ns ubsection(2) (a) ort ot he disease, injuryo ri llnesso rr isko f disease, injuryo ri llnessr eferredt o ins ubsection(2) (b).

Jointa ndsev eral liabilityin a na ctionu ndersect ion2 (1)

4 (1) Twoo rm ore defendantsi nan ac tionu nders ection2 (1) are jointlyan d severallyl iable fort he costo f healthc are benefitsi f

(a) those defendantsjo intlyb reached a dutyo ro bligationd escribedi n the definitiono f "opioid-relatedw rong" ins ection1 (1), and

(b) as a consequence of the breachd escribedi np aragraph (a) of this subsection, atl easto ne of those defendantsi sh eldl iable int he action unders ection2 (1) fort he costo f those healthc are benefits.

(2) Forp urposeso f anac tionu nders ection2 (1), 2o rm ore manufacturerso r wholesalers, whethero rn ott heyar e defendantsi nt he action, are deemedt o have jointlyb reached a dutyo ro bligationd escribedi nt he definitiono f "opioid-relatedw rong" ins ection1 (1) if

(a) one orm ore of those manufacturerso rw holesalersar e heldt oh ave breachedt he dutyo ro bligation, and

(b) atc ommonl aw, ineq uityo ru ndera nen actment, those manufacturerso rw holesalersw ouldb e held

(i) toh ave conspiredo rac tedi nc oncertw ithr espectt ot he breach,

(ii) toh ave actedi n a principalan dag entr elationshipw itheac h otherw ithr espectt ot he breach, or

(iii) tob e jointlyo rv icariouslyl iable fort he breachi f damages wouldh ave beena wardedt o a personw hos ufferedd amagesas a consequence of the breach.

Population-basedev idence toes tablishca usationa ndq uantifyd amages orco st

5 Statisticali nformationan di nformationd erivedfr omep idemiological, sociological ando therr elevants tudies, includingi nformationd erivedfr oms ampling, is admissible asev idence fort he purposeso f establishingc ausationan dq uantifying damageso rt he costo f healthc are benefitsr espectingan o pioid-relatedw rongi n anac tionb rought

(a) byo ro nb ehalf of a person, int he person'so wnn ame oras a membero f a classo f personsu ndert he *ClassPr oceedingsA ct*, or

(b) byt he governmentu nders ection2 (1).

Limitationp eriods

6 (1) Noac tiont hati sc ommencedb yt he governmentw ithin2 y earsaft ert he comingi ntofo rce of thiss ectionfo rt he recoveryo f the costo f healthc are benefits, orfo rd amages, allegedt oh ave beenc ausedo rc ontributedt ob yan opioid-relatedw rong, isb arredu ndert he *LimitationA ct*.

(2) Anyac tiond escribedi ns ubsection(1) of thiss ectionfo rd amagesal legedt o have beenc ausedo rc ontributedt ob yan o pioid-relatedw rongi sr evivedi f the actionw asd ismissedb efore the comingi ntofo rce of thiss ectionm erely because itw ash eldb y a courtt ob eb arredo rex tinguishedb yt he *Limitation Act*.

Liabilityb asedo nr iskco ntribution

7 (1) Thiss ectionap pliest oan ac tionfo rt he recoveryo f the costo f healthc are benefits, orfo rd amages, allegedt oh ave beenc ausedo rc ontributedt ob yan opioid-relatedw rong, othert hanan ac tionfo rt he recoveryo f the costo f healthc are benefitso nan ag gregate basis.

(2) If the governmenti su nable toes tablishw hichd efendantc ausedo rc ontributed tot he use orex posure describedi np aragraph(b) and, as a resulto f ab reach of a commonl aw, equitable ors tatutoryd utyo ro bligation,

(a) one orm ore defendantsc auseso rc ontributest o a risko f disease, injuryo ri llnessb ym aking a type of opioidp roducta vailable to insuredp ersons, and

(b) ani nsuredp ersonh asu sedo rb eenex posedt ot he type of opioid productr eferredt oi np aragraph (a) ands uffersd isease, injuryo r illnessas a resulto f the use orex posure,

the courtm ayfi ndeac hd efendantt hatc ausedo rc ontributedt ot he risko f disease, injuryo ri llnessl iable for a proportiono f the damageso rc osto f healthc are benefitsi ncurred, equalt ot he proportiono f itsc ontributiont ot hat risko f disease, injuryo ri llness.

(3) The courtm ayc onsidert he followingi nap portioningl iabilityu nders ubsection (2):

(a) the lengtho f time a defendanten gagedi nt he conductt hatc ausedo r contributedt ot he risko f disease, injuryo ri llness;

(b) the markets hare a defendanth adi nt he type of opioidp roductt hat causedo rc ontributedt ot he risko f disease, injuryo ri llness;

(c) the degree of potencyo f the opioidp roductm anufacturedo r promotedb y a defendant;

(d) the amounts pentb y a defendanto np romotingt he type of opioid productt hatc ausedo rc ontributed tot he risko f disease, injuryo r illness;

(e) the degree tow hich a defendantc ollaboratedo rac tedi nc oncertw ith otherm anufacturerso rw holesalersi nan yc onductt hatc aused, contributedt oo rag gravatedt he risko f disease, injuryo ri llness;

(f) the extentt ow hich a defendantc onductedt estsan ds tudiest o determine the risko f disease, injuryo ri llnessr esultingfr omu se of or exposure tot he type of opioidp roduct;

(g) the extentt ow hich a defendantas sumed a leadershipr ole in manufacturingo rp romotingt he type of opioidp roduct;

(h) the efforts a defendantm ade tow arnp ractitionersan dt he public aboutt he risko f disease, injuryo ri llnessr esultingfr omu se of or exposure tot he type of opioidp roduct;

(i) the extentt ow hich a defendantc ontinuedm anufacturingo r promotingt he type of opioidp roductaft eri tk newo ro ughtt oh ave knownt he risko f disease, injuryo ri llnessr esultingfr omu se of or exposure tot he type of opioidp roduct;

(j) the extentt ow hich a defendantc ontinuedp romotingt he type of opioidp roductaft eri tk newo ro ughtt oh ave knownt hatt he amount ord osage of the type of opioidp roductp romotedd idn otr easonably reflectt he healthn eedso f the populationo f insuredp ersonsw ho were likelyt ou se orb e exposedt ot he type of opioidp roduct;

(k) affirmative stepst hat a defendantt ookt or educe the risko f disease, injuryo ri llnesst ot he public;

(l) otherc onsiderationsc onsideredr elevantb yt he court.

Apportionmento f liabilityin o pioid-relatedw rongs

8 (1) Thiss ectiond oesn otap plyt o a defendanti nr especto f whomt he courth as made a findingo f liabilityu nders ection7 .

(2) A defendantw hoi sfo undl iable for ano pioid-relatedw rongm ayc ommence, againsto ne orm ore of the defendantsfo undl iable fort hatw rongi nt he same action, anac tiono rp roceedingfo rc ontributiont owardt he costo f healthc are benefitso rt he paymento f damagesc ausedo rc ontributedt ob yt hatw rong.

(3) Subsection(2) of thiss ectionap pliesw hethero rn ott he defendant commencingan ac tiono rp roceedingu ndert hats ubsectionh asp aidal lo ran y of the costo f healthc are benefitso rt he damagesc ausedo rc ontributedt ob y the opioid-relatedw rong.

(4) Inan ac tiono rp roceedingd escribedi ns ubsection(2) of thiss ection, the court mayap portionl iabilityan do rderc ontributionam ongeac ho f the defendantsi n accordance witht he considerations listedi ns ection7 (3).

Regulations

9 (1) The LieutenantG overnori nCo uncilm aym ake regulationsr eferredt oi n section4 1o f the *InterpretationA ct*.

(2) Withoutl imitings ubsection(1) of thiss ection, the LieutenantG overnori n Councilm aym ake regulationsp rescribingd rugsfo rt he purposeso f paragraph (b) of the definitiono f "opioidp roduct" ins ection1 (1).

Retroactive effect

10 A provisiono f thisAc th ast he retroactive effectn ecessaryt og ive the provisionfu ll effectfo ral lp urposes, includingal lowingan ac tiont ob e broughtu nders ection2 (1) arisingfr oman o pioid-relatedw rong, whenevert he opioid-relatedw rong occurred.

If proceedings alreadyco mmenced

11 (1) If the governmenth asc ommenced a proceedingi nr elationt oan o pioid-relatedw rongan dt he proceedingi so ngoingas o f the date thiss ectionc omes intofo rce,

(a) the proceedingc ontinuesi nac cordance witht hisAc t,

(b) fort he purposeso f section4 o f the *ClassPr oceedingsA ct*, the governmentm ayb ringan ac tiono nb ehalf of a classc onsistingo f

(i) one orm ore of the governmento f Canada andt he government of a jurisdictionw ithinCan ada, and

(ii) a federalo rp rovincialg overnmentp aymentag encyt hatm akes reimbursementfo rt he costo f servicest hatar e int he nature of healthc are benefitsw ithint he meaningo f thisAc t,

(c) a procedure completed, andan o rderm ade, before thiss ectionc omes intofo rce continuest oh ave effectu nless

(i) itw ouldb e inconsistentw itht hisAc t, or

(ii) the courto rderso therwise, and

(d) a procedure thatb eganb utw asn otc ompletedb efore thiss ection comesi ntofo rce mustb e completedi nac cordance witht hisAc t.

(2) Nothingi ns ubsection(1) (b) of thiss ectionp revents a membero f the class describedi nt hatp rovisionfr omo ptingo uto f the proceedingi nac cordance withs ection1 6o f the *ClassPr oceedingsA ct*.

Effecto f existinga greements

12 (1) Ins ubsections(2) and(3) of thiss ection, **"proceeding"**m eans a proceeding

(a) inr elationt oan ac tiont akenu nders ection2 (1) of thisAc t, or

(b) continuedas d escribedi ns ection1 1o f thisAc t.

(2) Despite anyp riorag reementt hatp urportst ob indt he governmenti nr elation toc ompensationar isingfr oman o pioid-relatedw rong,

(a) the governmenti sn otb arredfr om commencingo rc ontinuinga proceeding,

(b) the evidence thatm ayb e broughta gainst a partyt ot he agreementi n the course of a proceedingi sn otl imited, and

(c) the liabilityo f, ort he amounto f compensationp ayable by, a partyt o the agreementi nr elationt oan o pioid-relatedw rongt hati st he subjecto f a proceedingi sn otl imited.

(3) If anag reementd escribedi ns ubsection(2) of thiss ectionh asb eenfi nalized byr eceivingt he consento f allp artiest ot he agreementan dal ln ecessaryc ourt approvals, if any, before the date thisAc tr eceivesR oyalAs sent, any compensationr eceivedb yt he governmentu ndert he agreementm ustb e deductedfr oman yc ompensationr eceivedb yt he governmentas a resulto f a proceeding.

(4) Noc ompensationi sp ayable byt he governmentan dp roceedingsm ustn otb e commencedo rc ontinuedt oc laimc ompensationfr omt he governmento rt o obtain a declarationt hatc ompensationi sp ayable byt he governmentas a resulto f the voidingo f anag reementd escribedi ns ubsection(2) of this section.

Consequential Amendment

[Note: See Table of Legislative Changesfo rt he statuso f section1 3.]

Section(s)	AffectedA ct
13	*Health Care Costs Recovery Act*

Commencement

14 ThisAc tc omesi ntofo rce ont he date of RoyalAs sent.

Schedule

(Section1)

Opioidp roducts

1 A productt hatc ontainsan yo f the followingd rugsi san o pioidp roductfo rt he purposeso f thisAc t:

Drugsc ontaininga nyo ft hef ollowing activein gredients	Includingb utn otlim itedt o
Anileridine	
Buprenorphine	Buprenorphine Hydrochloride
Butorphanol	Butorphanol Tartrate
Codeine, except for those products referred to in section 36 (1) of the Narcotic Control Regulations (Canada)	Codeine Phosphate
Diacetylmorphine	
Fentanyl	Fentanyl Citrate
Hydrocodone	Hydrocodone Bitartrate
Hydromorphone	Hydromorphone Hydrochloride
Levorphanol	
Meperidine	Meperidine Hydrochloride
Methadone	Methadone Hydrochloride
Morphine	Morphine Hydrochloride and Morphine Sulfate
Nalbuphine	
Normethadone	Normethadone Hydrochloride
Opium	Opium and Belladonna
Oxycodone	Oxycodone Hydrochloride
Oxymorphone	Oxymorphone Hydrochloride
Pentazocine	Pentazocine Hydrochloride and Pentazocine Lactate
Propoxyphene	
Remifentanil	
Sufentanil	
Tapentadol	Tapentadol Hydrochloride
Tramadol	Tramadol Hydrochloride